In September 2024, InvestingPro’s Fair Value models identified Viking Therapeutics (NASDAQ:VKTX) as significantly overvalued at $31.42 per share. This assessment has proven remarkably accurate over ...
SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ:VKTX) announced Thursday it has completed patient enrollment in its exploratory maintenance dosing study of VK2735, the company’s dual GLP-1/GIP receptor ...
SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ:VKTX) announced Wednesday the appointment of Neil Aubuchon as chief commercial officer, according to a company press release. The clinical-stage biotech, ...
Following these transactions, Foehr directly owns 135,186 shares of Viking Therapeutics. In other recent news, Viking Therapeutics has completed patient enrollment for its Phase 3 VANQUISH-1 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results